Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Robert Seifert; Louise Emmett; Steven P. Rowe; Ken Herrmann; Boris Hadaschik; Jérémie Calais; Frederik L. Giesel; Robert E. Reiter; Tobias Maurer; Matthias Heck; Andrei Gafita; Michael J. Morris; Stefano Fanti; Wolfgang Weber; Thomas A. Hope; Michael S. Hofman; Wolfgang P. Fendler; Matthias Eiber

doi:10.1016/j.eururo.2023.02.002

Abstract

This is the authors' abstract. We don't add key points for this paper.

Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) has become a standard imaging examination for prostate cancer. We propose a comprehensive framework for the analysis and reporting of PSMA-PET findings that will improve the communication between imaging experts and uro-oncologists.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Seifert et al. (2023) studied this question.

synapsesocial.com/papers/69da1ad184371aa676a3c9b8 https://doi.org/10.1016/j.eururo.2023.02.002

View Full Paper

Ask AI

Bookmark

Share

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Abstract

Ask about this paper

Discussion

Cite This Study

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading